Intravenous ibandronate or sodium-fluoride-a 3.5 years study on bone density and fractures in Crohn's disease patients with osteoporosis

Journal of Gastrointestinal and Liver Diseases

Volumn 20, Issue 2, 2011, Pages 141-148

  Klaus, Jochen ^a   Reinshagen, Max ^b   Herdt, Katharina ^a   Adler, Guido ^a   von Boyen, Georg B T ^a   von Tirpitz, Christian ^c  

^a UNIVERSITY OF ULM   (Germany)

^b KLINIKUM BRAUNSCHWEIG   (Germany)

^c Medizinische Klinik   (Germany)

Author keywords

Calcium; Colecalciferol; Crohn's disease; Fluoride; Ibandronate; Osteoporosis; Sodium

Indexed keywords

CALCITRAT; CITRATE CALCIUM; COLECALCIFEROL; FLUORIDE SODIUM; IBANDRONIC ACID; NAFRIL; UNCLASSIFIED DRUG; VIGANTOLETTEN;

ADULT; ARTICLE; BONE DENSITOMETRY; BONE DENSITY; CROHN DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR; FRACTURE; HUMAN; LUMBAR OSTEOPOROSIS; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; SUSTAINED DRUG RELEASE;

ABSORPTIOMETRY, PHOTON; ADULT; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCIUM CITRATE; CHOLECALCIFEROL; CROHN DISEASE; DELAYED-ACTION PREPARATIONS; DIPHOSPHONATES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; OSTEOPOROSIS; PREVALENCE; SODIUM FLUORIDE; SPINAL FRACTURES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79960102885     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Compston JE, Judd D, Crawley EO, et al. Osteoporosis in patients with inflammatory bowel disease. Gut 1987; 28: 410-415.
2. Abitbol V, Roux C, Chaussade S, et al. Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology 1995; 108: 417-422.
3. Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C. Reduced bone density in patients with inflammatory bowel disease. Gut 1997; 40: 228-233.
4. Jahnsen J, Falch JA, Aadland E, Mowinckel P. Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study. Gut 1997; 40: 313-319.
5. Von Tirpitz C, Pischulti G, Klaus J, et al. Pathological bone density in chronic inflammatory bowel diseases-prevalence and risk factors. Z Gastroenterol 1999; 37: 5-12.
6. Silvennoinen JA, Karttunen TJ, Niemela SE, Manelius JJ, Lehtola JK. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut 1995; 37: 71-76.
7. Deutsche Morbus Crohn/Colitis ulcerosa Vereinigung e.V. (DCCV). Available at: http://www.dccv.de/ Accessed August 2010.
8. Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med 2000; 133: 795-799.
9. Vestergaard P, Krogh K, Rejnmark L, Laurberg S, Mosekilde L. Fracture risk is increased in Crohn's disease, but not in ulcerative colitis. Gut 2000; 46: 176-181.
10. Klaus J, Armbrecht G, Steinkamp M, et al. High prevalence of osteoporotic vertebral fractures in patients with Crohn's disease. Gut 2002; 51: 654-658.
11. van Staa TP, Cooper C, Brusse LS, Leufkens H, Javaid MK, Arden NK. Inflammatory bowel disease and the risk of fracture. Gastroenterology 2003; 125: 1591-1597.
12. Bernstein CN, Seeger LL, Sayre JW, Anton PA, Artinian L, Shanahan F. Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. J Bone Miner Res 1995; 10: 250-256.
13. von Tirpitz C, Epp S, Klaus J, et al. Effect of systemic glucocorticoid therapy on bone metabolism and the osteoprotegerin system in patients with active Crohn's disease. Eur J Gastroenterol Hepatol 2003; 15: 1165-1170.
14. Schulte CM, Dignass AU, Goebell H, Roher HD, Schulte KM. Genetic factors determine extent of bone loss in inflammatory bowel disease. Gastroenterology 2000; 119: 909-920.
15. Siffledeen JS, Fedorak RN, Siminoski K, et al. Bones and Crohn's: risk factors associated with low bone mineral density in patients with Crohn's disease. Inflamm Bowel Dis 2004; 10: 220-228.
16. Todhunter CE, Sutherland-Craggs A, Bartram SA, et al. Influence of IL-6, COL1A1, and VDR gene polymorphisms on bone mineral density in Crohn's disease. Gut 2005; 54: 1579-1584.
17. Bartram SA, Peaston RT, Rawlings DJ, Walshaw D, Francis RM, Thompson NP. Mutifactorial analysis of risk factors for reduced bone mineral density in patients with Crohn's disease. World J Gastroenterol 2006; 12: 5680-5686.
18. Tilg H, Moschen AR, Kaser A, Pines A, Dotan I. Gut, inflammation and osteoporosis: basic and clinical concepts. Gut 2008; 57: 684-694.
19. Klaus J, Reinshagen M, Adler G, Boehm B, von Tirpitz C. Bones and Crohn's: estradiol deficiency in men with Crohn's disease is not associated with reduced bone mineral density. BMC Gastroenterol 2008; 8: 48.
20. Leslie WD, Miller N, Rogala L, Bernstein CN. Vitamin D status and bone density in recently diagnosed inflammatory bowel disease: the Manitoba IBD Cohort Study. Am J Gastroenterol. 2008; 103: 1451-1459.
21. Vogelsang H, Ferenci P, Resch H, Kiss A, Gangl A. Prevention of bone mineral loss in patients with Crohn's disease by long-term oral vitamin D supplementation. Eur J Gastroenterol Hepatol 1995; 7: 609-614.
22. Clements D, Compston JE, Evans WD, Rhodes J. Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease. Gut 1993; 34: 1543-1546.
23. von Tirpitz C, Klaus J, Bruckel J, et al. Increase of bone mineral density with sodium fluoride in patients with Crohn's disease. Eur J Gastroenterol Hepatol 2000; 12: 19-24.
24. Haderslev KV, Tjellesen L, Sorensen HA, Staun M. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. Gastroenterology 2000; 119: 639-646.
25. Siffledeen JS, Fedorak RN, Siminoski K, et al. Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease. Clin Gastroenterol Hepatol 2005; 3: 122-132.
26. Cosman F. Treatment of osteoporosis and prevention of new fractures: role of intravenously administered bisphosphonates. Endocr Pract 2009; 15: 483-493.
27. Weycker D, Macarios D, Edelsberg J, Oster G. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 2006; 17: 1645-1652.
28. Bartram SA, Peaston RT, Rawlings DJ, Francis RM, Thompson NP. A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease. Aliment Pharmacol Ther 2003; 18: 1121-1127.
29. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994; 843: 1-129.
30. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439-444.
31. Eastell R, Cedel SL, Wahner HW, Riggs BL, Melton LJ 3rd. Classification of vertebral fractures. J Bone Miner Res 1991; 6: 207-215.
32. McCloskey EV, Spector TD, Eyres KS, et al. The assessment of vertebral deformity: a method for use in population studies and clinical trials. Osteoporos Int 1993; 3: 138-147.
33. Black DM, Palermo L, Nevitt MC, Genant HK, Christensen L, Cummings SR. Defining incident vertebral deformity: a prospective comparison of several approaches. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1999; 14: 90-101.
34. Felsenberg D, Wieland E, Gowin W, et al. Morphometric analysis of roentgen images of the spine for diagnosis of osteoporosis-induced fracture. Med Klin (Munich) 1998; 93 Suppl 2: 26-30.
35. Felsenberg D, Armbrecht G, Khorassani A. Europäische Prospektive Osteoporosestudie (EPOS). Förderungsprojekt des Bundesministeriums für Bildung, Wissenschaft, Forschung und Technologie (BMBF). Förderkennzeichen 01 KM 9402/3.
36. Stein CM, Ray WA. The ethics of placebo in studies with fracture end points in osteoporosis. N Engl J Med 2010; 363: 1367-1370; discussion e21.
37. Pak CY, Sakhaee K, Adams-Huet B, Piziak V, Peterson RD, Poindexter JR. Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial. Ann Intern Med 1995; 123: 401-408.
38. Riggs BL, Hodgson SF, O'Fallon WM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990; 322: 802-809.
39. Rubin CD, Pak CY, Adams-Huet B, Genant HK, Li J, Rao DS. Sustained-release sodium fluoride in the treatment of the elderly with established osteoporosis. Arch Intern Med 2001; 161: 2325-2333.
40. Vestergaard P, Jorgensen NR, Schwarz P, Mosekilde L. Effects of treatment with fluoride on bone mineral density and fracture risk--a meta-analysis. Osteoporos Int 2008; 19: 257-268.
41. Weycker D, Macarios D, Edelsberg J, Oster G. Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos Int 2007; 18: 271-277.
42. Pecherstorfer M, Ludwig H, Schlosser K, Buck S, Huss HJ, Body JJ. Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection. J Bone Miner Res 1996; 11: 587-593.
43. Thiebaud D, Burckhardt P, Kriegbaum H, et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 1997; 103: 298-307.
44. Sebba AI, Emkey RD, Kohles JD, Sambrook PN. Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: results of a meta-analysis. Bone 2009; 44: 423-427.
45. Eisman JA, Civitelli R, Adami S, et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol 2008; 35: 488-497.